I now have comprehensive content from multiple authoritative textbooks. Let me compile the full detailed answer for MD exams: --- # High Altitude Physiology - Complete MD Exam Answer (10 Marks) --- ## 1. DEFINITION OF HIGH ALTITUDE Altitude is classified into physiologically meaningful stages: | Stage | Altitude | Effects | |---|---|---| | Intermediate | 1520-2440 m | Decreased exercise performance, mild hyperventilation | | High | 2440-4270 m | Decreased SaO₂; AMS risk begins ~2130 m | | Very high | 4270-5490 m | Severe hypoxemia at rest; acclimatization required | | Extreme | >5490 m | Severe hypoxemia + hypocapnia; no permanent habitation possible | At Mount Everest summit (8848 m): PB = ~253 mmHg (1/3 of sea level), inspired PO₂ = only **43 mmHg** (vs. 159 mmHg at sea level). --- ## 2. THE OXYGEN CASCADE AT HIGH ALTITUDE Barometric pressure (PB) falls exponentially with altitude - it halves every ~5500 m. Since O₂ concentration in air remains constant at 21%, PO₂ falls proportionally: - **Sea level**: PB = 760 mmHg, Inspired PO₂ = 159 mmHg, PaO₂ = 90-95 mmHg - **4570 m (15,000 ft)**: PaO₂ = 48-53 mmHg, SaO₂ = 86% - **8848 m (summit)**: PaO₂ = 26-33 mmHg, SaO₂ = 58%, PaCO₂ = 9.5-13.8 mmHg The **Hb-O₂ dissociation curve** provides partial protection: up to ~3000 m, PaO₂ falls on the flat part of the curve, so SaO₂ and O₂ content are relatively preserved. Above this, the steep portion is reached and O₂ content drops sharply. At very high altitudes, **diffusion limitation** also occurs - pulmonary capillary blood fails to equilibrate with alveolar PO₂ before leaving the capillary, especially during exercise. --- ## 3. ACCLIMATIZATION - ADAPTIVE RESPONSES ### A. Pulmonary Acclimatization (Ventilatory Response) **Acute response (minutes to hours):** - Hypoxemia is sensed by **carotid body peripheral chemoreceptors** - Triggers **hypoxic ventilatory response (HVR)** - immediate rise in ventilation - HVR raises alveolar PO₂ toward ambient PO₂ - Hyperventilation blows off CO₂ → **respiratory alkalosis** (↓PaCO₂, ↑pH) - This alkalosis acts as a **brake** on the ventilatory drive (especially via medullary chemoreceptors) - Net effect: ventilation at 4500 m is only ~2x sea level (not the maximal possible drive) - Heart rate also increases due to sympathetic activation **Ventilatory acclimatization (days to weeks):** - Over 4-7 days, ventilation progressively increases further - **Renal compensation** - bicarbonate excretion normalizes pH → removes the brake - Medullary chemoreceptors reset to lower PaCO₂ setpoint - Final PaCO₂ at extreme altitude can fall to 9-14 mmHg - Acetazolamide facilitates this by inducing bicarbonate diuresis (carbonic anhydrase inhibition) ### B. Cardiovascular Acclimatization **Acute phase:** - Sympathetic activation → **tachycardia** → increased cardiac output → compensates for decreased O₂ content - Peripheral vasoconstriction → increased central blood volume **Weeks to months:** - Resting heart rate returns toward normal - **Pulmonary vasoconstriction (hypoxic pulmonary vasoconstriction - HPV)** - redistributes blood flow to better-ventilated alveoli - Right ventricular afterload increases (HPV is a double-edged sword) - Blood volume initially contracts (from diuresis), then increases with polycythemia ### C. Hematologic Acclimatization - Within **hours**: serum erythropoietin (EPO) rises (HIF-1α mediated hypoxic response) - Over **days to weeks**: red cell mass increases (polycythemia) - Hematocrit rises (up to 55-60% at very high altitudes) - **2,3-DPG (2,3-bisphosphoglycerate)** increases → right shift of Hb-O₂ curve → facilitates O₂ unloading in tissues - Respiratory alkalosis simultaneously produces a **left shift** → facilitates O₂ loading in lungs - These opposing effects largely cancel out (Haldane effect) ### D. Tissue/Cellular Acclimatization - Increased capillary density in skeletal muscle (angiogenesis via VEGF) - Increased mitochondrial density - Shift to more efficient oxidative metabolism - HIF-1α activates genes for glycolysis, erythropoiesis, angiogenesis, and vasomotor tone ### E. Renal Acclimatization / Fluid Balance - Peripheral venous constriction → increased central blood volume → triggers **diuresis and natriuresis** (via ANP, suppressed ADH) - Plasma volume falls (hemoconcentration in early phases) - Renal bicarbonate excretion compensates for respiratory alkalosis - Aldosterone may increase in some individuals → sodium/water retention (a maladaptive response, promoting AMS) ### F. CNS Acclimatization - Cerebral blood flow **increases acutely** (hypoxic vasodilation) - helps maintain O₂ delivery - Hyperventilation reduces PaCO₂ → **cerebral vasoconstriction** (counteracts the above) - Net: modest cerebral vasoconstriction but maintained O₂ delivery - Sleep is disturbed at altitude - **periodic breathing (Cheyne-Stokes respiration)** occurs due to oscillations in hypoxic/hypocapnic drives; more hypoxemia during sleep than waking --- ## 4. MALADAPTATION - ALTITUDE ILLNESSES Any person ascending too fast to >2500 m risks one of three syndromes: ### A. Acute Mountain Sickness (AMS) - **Incidence**: 22-50% at 1850-4240 m - **Onset**: 6-12 hours after arrival; peaks at 24-48 hours - **Lake Louise Criteria**: headache + at least one of nausea/vomiting, fatigue/weakness, dizziness, poor sleep - **Pathophysiology**: vasogenic cerebral edema from hypoxia-driven neuroinflammation, impaired cerebrovascular autoregulation, and raised ICP - **Treatment**: acetazolamide 250 mg BD, dexamethasone 4-8 mg, supplemental O₂; descent if severe ### B. High-Altitude Cerebral Edema (HACE) - Severe end of AMS spectrum - life threatening - Features: severe headache, ataxia (tandem gait failure), altered consciousness, papilledema - **Pathophysiology**: vasogenic and cytotoxic edema, raised ICP, possible cerebral herniation - **Treatment**: **immediate descent** is mandatory; dexamethasone 8 mg IV/IM/PO then 4 mg q6h; portable hyperbaric bag (Gamow bag); supplemental O₂ ### C. High-Altitude Pulmonary Edema (HAPE) - **Most lethal** form of altitude illness; mortality >50% if untreated - **Incidence**: 0.5-15% depending on altitude and rate of ascent - **Onset**: 2-4 days after ascent above 2500 m - **Features**: dry cough → frothy pink sputum, dyspnoea at rest, cyanosis, decreased exercise tolerance, crackles on auscultation - **Pathophysiology**: - Exaggerated HPV → uneven pulmonary vasoconstriction → overperfusion of some capillary beds → **non-cardiogenic pulmonary edema** from elevated capillary pressure - HAPE-susceptible individuals have intense HPV and exaggerated pulmonary vascular responses - Inflammatory cells and mediators also contribute - **Treatment**: **descent 300-1000 m** immediately; nifedipine 30 mg slow-release (↓pulmonary vascular resistance); supplemental O₂ is most effective; tadalafil/sildenafil (PDE5 inhibitors) as alternatives; dexamethasone; portable hyperbaric chamber --- ## 5. CHRONIC MOUNTAIN SICKNESS (Monge's Disease) - Affects long-term high-altitude residents - Features: excessive polycythemia (Hct >55%), headache, fatigue, cyanosis, right heart failure (cor pulmonale) - Pathophysiology: Hb >21 g/dL → hyperviscosity → reduced O₂ delivery paradoxically - Treatment: phlebotomy, descent, acetazolamide, medroxyprogesterone --- ## 6. HIGH-ALTITUDE RETINOPATHY - Retinal hemorrhages at >5000 m; usually asymptomatic unless affecting the macula - Due to increased retinal blood flow and vessel permeability under hypoxic conditions - Flame-shaped and dot hemorrhages on fundoscopy --- ## 7. PHARMACOLOGY AT HIGH ALTITUDE | Drug | Mechanism | Use | |---|---|---| | **Acetazolamide** | Carbonic anhydrase inhibitor → bicarbonate diuresis → metabolic acidosis → stimulates ventilation | Prevention and treatment of AMS; facilitates acclimatization | | **Dexamethasone** | Reduces vasogenic cerebral edema, anti-inflammatory | Treatment of AMS/HACE | | **Nifedipine** | Ca-channel blocker → ↓HPV → ↓pulmonary artery pressure | HAPE prevention and treatment | | **Sildenafil/Tadalafil** | PDE5 inhibition → ↑cGMP → pulmonary vasodilation | HAPE prevention | | **Supplemental O₂** | Raises alveolar PO₂ | All altitude illnesses | --- ## 8. KEY PRINCIPLES FOR PREVENTION - "Climb high, sleep low" principle - Acclimatization above 3000 m: ascend no more than **300-500 m per day** in sleeping altitude - Rest day every 3rd day - Acetazolamide prophylaxis: 125-250 mg BD starting 24 h before ascent - Fitness does NOT protect against altitude illness --- ## 9. SUMMARY TABLE - PHYSIOLOGICAL CHANGES AT HIGH ALTITUDE | Parameter | Acute | Chronic (Acclimatized) | |---|---|---| | Ventilation | ↑ | ↑↑ (maximal) | | PaCO₂ | ↓ | ↓↓ | | pH | ↑ (resp. alkalosis) | ~normal (compensated) | | HCO₃⁻ | Normal | ↓ (renal compensation) | | Heart rate | ↑↑ | ↑ mild | | Cardiac output | ↑ | Normal/↑ | | Hematocrit | Normal/slight ↑ | ↑↑ | | EPO | ↑ (within hours) | ↑ (sustained) | | 2,3-DPG | Normal | ↑ | | Pulmonary artery pressure | ↑ | ↑ (HPV) | | Cerebral blood flow | ↑ | ~normal | --- **Sources:** Guyton & Hall Textbook of Medical Physiology; Murray & Nadel's Textbook of Respiratory Medicine, Ch. 105; Tintinalli's Emergency Medicine, Ch. 216; Medical Physiology (Boron & Boulpaep), Ch. 61

Repeat the same answer